Magnusiomyces clavatus fungemia treated with combination antifungals including isavuconazole in an immunocompromised pediatric patient: a case report. (PubMed, Ther Adv Infect Dis) - Jul 26, 2026 - "Intrinsic resistance to fluconazole and echinocandins has been theorized; however, little else is known regarding optimal treatment regimens for this opportunistic pathogen. To our knowledge, only 13 infectious cases have been described in pediatric patients, all of which utilized a combination of antifungals including liposomal amphotericin B (LAmB) and voriconazole with or without flucytosine (5-FC)...The patient was empirically treated with LAmB, micafungin, and posaconazole (POS), the latter of which failed to reach therapeutic levels. Ultimately, our patient defervesced and cleared blood cultures after transitioning LAmB to 5-FC, followed by definitive treatment with isavuconazole (ISA) monotherapy. To our knowledge, this is the first case of pediatric M. clavatus ultimately treated with 5-FC plus POS followed by ISA alone."
Journal • Aplastic Anemia • Febrile Neutropenia • Hematological Disorders • Infectious Disease • Neutropenia • Pediatrics • Transplantation
|
|
Amanda Z McPherson; Kacie Rytlewski; Kira E Frappa; Matthew Miller; Samantha Bacon
|